• 1
    NIH consensus conference. Treatment of early-stage breast cancer. JAMA. 1991; 265: 391-395.
  • 2
    Carlson RW, Goldstein LJ, Gradishar WJ, et al. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996; 10( 11 suppl): 47-75.
  • 3
    Consensus Conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985; 254: 3461-3463.
  • 4
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 5
    Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003; 138: 90-97.
  • 6
    Woodard S, Nadella PC, Kotur L, Wilson J, Burak WE, Shapiro CL. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias? Cancer. 2003; 98: 1141-1149.
  • 7
    Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006; 24: 2757-2764.
  • 8
    Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006; 24: 2750-2756.
  • 9
    Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci. 2005; 60: 1137-1144.
  • 10
    Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005; 293: 1073-1081.
  • 11
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40( 8 suppl): IV-55-IV-61.
  • 12
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( 8 suppl): IV-3-IV-18.
  • 13
    Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren J. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002; 40( 8 suppl): IV-82-IV-95.
  • 14
    American Medical Association (AMA). Division of Survey and Data Resources. Physician master file. 2007.
  • 15
    Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002; 20: 4636-4642.
  • 16
    Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660-669.
  • 17
    Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RGJr. Assessing illness severity: does clinical judgment work? J Chronic Dis. 1986; 39: 439-452.
  • 18
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 19
    Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988; 44: 1049-1060.
  • 20
    Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med. 2006; 26: 2017-2035.
  • 21
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006; 98: 839-845.
  • 22
    Hershman DL, Buono D, McBride RB, et al. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. J Natl Cancer Inst. 2008; 100: 199-206.
  • 23
    Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer. 2007; 109: 975-982.
  • 24
    Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002; 20: 1786-1792.
  • 25
    Franks P, Williams GC, Zwanziger J, Mooney C, Sorbero M. Why do physicians vary so widely in their referral rates? J Gen Intern Med. 2000; 15: 163-168.
  • 26
    Freiman MP. The rate of adoption of new procedures among physicians. The impact of specialty and practice characteristics. Med Care. 1985; 23: 939-945.
  • 27
    Shen J, Andersen R, Brook R, Kominski G, Albert PS, Wenger N. The effects of payment method on clinical decision-making: physician responses to clinical scenarios. Med Care. 2004; 42: 297-302.
  • 28
    Mort EA, Edwards JN, Emmons DW, Convery K, Blumenthal D. Physician response to patient insurance status in ambulatory care clinical decision-making. Implications for quality of care. Med Care. 1996; 34: 783-797.
  • 29
    Hickson GB, Altemeier WA, Perrin JM. Physician reimbursement by salary or fee-for-service: effect on physician practice behavior in a randomized prospective study. Pediatrics. 1987; 80: 344-350.
  • 30
    Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006; 11: 90-95.
  • 31
    Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007; 25: 233-237.
  • 32
    Abelson R. Drug sales bring huge profits, and scrutiny, to cancer doctors. New York Times (Business Section); Jan. 26, 2003.
  • 33
    Bloom BS, de Pouvourville N, Chhatre S, Jayadevappa R, Weinberg D. Breast cancer treatment in clinical practice compared to best evidence and practice guidelines. Br J Cancer. 2004; 90: 26-30.
  • 34
    Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003; 41: 442-446.